ASND · Insider Trading
Ascendis Pharma A/S Ordinary Share
Every open-market purchase and sale reported by ASND officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-28 | Jean Jacques Bienaime | Director | MIXED | — | — |
| 2026-09-09 | Mads Bodenhoff | SVP & PAO | MIXED | — | −$480.57K |
| 2026-09-03 | Lars Holtug | Director | Sell | −236 | −$62.33K |
| 2026-08-18 | Jean Jacques Bienaime | Director | Buy | +2,000 | +$492.65K |
| 2026-06-02 | Scott Thomas Smith | EVP & Chief Financial Officer | Buy | +100 | +$21.90K |
| 2026-06-01 | Scott Thomas Smith | EVP & Chief Financial Officer | Buy | +250 | +$55.83K |
| 2026-06-01 | Jean Jacques Bienaime | Director | Buy | +500 | +$111.56K |
| 2026-05-27 | Jean Jacques Bienaime | Director | Buy | +400 | +$95.12K |
| 2026-05-12 | Flemming Steen Jensen | See Remarks | Sell | −19,460 | −$4.64M |
| 2019-09-03 | Adrian Rawcliffe | CEO and CFO | A | +769,320 deriv. | — |
| 2019-08-07 | Rafael Amado | President, R&D | Sell | −11,043 | −$22.75K |
| 2019-08-05 | John Lunger | Chief Patient Supply Officer | A | +1,027,068 deriv. | — |
| 2019-07-03 | Barbara Gayle Duncan | Director | A | +124,000 deriv. | — |
| 2019-07-03 | Ali Behbahani | Director | A | +234,407 deriv. | — |
| 2019-07-03 | Lawrence M Alleva | Director | A | +271,209 deriv. | — |
| 2019-07-03 | Tal Zvi Zaks | Director | A | +124,000 deriv. | — |
| 2019-07-03 | David M Mott | Director | A | +350,947 deriv. | — |
| 2019-07-03 | Giles Francis Bertram Kerr | Director | A | +124,000 deriv. | — |
| 2019-07-03 | John Furey | Director | A | +240,541 deriv. | — |
| 2019-07-03 | Charles Elliott Sigal | Director | A | +234,407 deriv. | — |
| 2019-06-27 | Adrian Rawcliffe | Chief Financial Officer | A | +769,320 deriv. | — |
| 2019-05-17 | James Noble | Chief Executive Officer | M | +1,773,100 | +$253.55K |
| 2019-01-16 | Rafael Amado | President, R & D | Sell | −3,028 | −$16.26K |
| 2019-01-16 | William C Bertrand JR | Chief Operating Officer | Sell | −2,271 | −$12.19K |
| 2019-01-16 | Adrian Rawcliffe | Chief Financial Officer | Sell | −3,084 | −$16.56K |
| 2019-01-16 | Gwendolyn Knowlton Binder-Scholl | Chief Technology Officer | Sell | −1,514 | −$8.13K |
| 2019-01-08 | James Noble | Chief Executive Officer | A | +3,077,328 deriv. | — |
| 2019-01-08 | Helen Katrina Tayton-Martin | Chief Business Officer | A | +1,230,948 deriv. | — |
| 2019-01-08 | William C Bertrand JR | Chief Operating Officer | A | +1,230,948 deriv. | — |
| 2019-01-08 | Rafael Amado | President, R & D | A | +1,230,948 deriv. | — |
| 2019-01-08 | Adrian Rawcliffe | Chief Financial Officer | A | +1,538,640 deriv. | — |
| 2018-12-19 | Lawrence M Alleva | Director | Buy | +47,280 | +$39.72K |
| 2018-10-02 | Gwendolyn Knowlton Binder-Scholl | Chief Technology Officer | Sell | −25,000 | −$344.75K |
| 2018-09-10 | Anthony A. Florence Jr. | 10%+ Owner | Buy | +15,000,000 | +$25.00M |
| 2018-09-10 | Ali Behbahani | Director | Buy | +12,000,000 | +$20.00M |
| 2018-09-10 | Forest Baskett | 10%+ Owner | Buy | +15,000,000 | +$25.00M |
| 2018-09-10 | NEA 14 GP, LTD | 10%+ Owner | Buy | +9,000,000 | +$15.00M |
| 2018-09-10 | Peter J Barris | 10%+ Owner | Buy | +15,000,000 | +$25.00M |
| 2018-09-10 | Ravi Viswanathan | 10%+ Owner | Buy | +15,000,000 | +$25.00M |
| 2018-09-10 | Scott D Sandell | 10%+ Owner | Buy | +15,000,000 | +$25.00M |
| 2018-09-10 | David M Mott | Director | Buy | +15,000,000 | +$25.00M |
| 2018-09-10 | Patrick J Kerins | 10%+ Owner | Buy | +3,000,000 | +$5.00M |
| 2018-09-10 | Peter W. Sonsini | 10%+ Owner | Buy | +15,000,000 | +$25.00M |
| 2018-09-10 | M James Barrett | 10%+ Owner | Buy | +3,000,000 | +$5.00M |
| 2018-08-31 | Gwendolyn Knowlton Binder-Scholl | Chief Technology Officer | Sell | −25,000 | −$256.25K |
| 2018-08-07 | Rafael Amado | President, R & D | A | +678,720 deriv. | — |
| 2018-06-26 | Charles Elliott Sigal | Director | A | +154,809 deriv. | — |
| 2018-06-26 | Giles Francis Bertram Kerr | Director | A | +124,000 deriv. | — |
| 2018-06-26 | Ali Behbahani | Director | A | +154,809 deriv. | — |
| 2018-06-26 | Lawrence M Alleva | Director | A | +124,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Scott Thomas Smith | EVP & Chief Financial Officer | 4,367 | $1.06M |
| Lars Holtug | Director | 4,000 | $971.96K |
| Jean Jacques Bienaime | Director | 2,000 | $485.98K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ASND quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.